Alterations of urinary excretion of antipyrine metabolites in patients with cirrhosis of the liver.

概要

論文の詳細を見る
Urinary metabolites of antipyrine, 3-hydroxymethylantipyrine (HMA), norantipyrine (NORA) and 4-hydroxyantipyrine (OHA) were determined with high performance liquid chromatography (HPLC) system in 13 patients with cirrhosis of the liver (including 8 with cirrhosis bearing hepatocellular carcinoma) and in 5 control subjects with oral administration of antipyrine (600mg per unit body surface area). Total antipyrine metabolites excreted in urine for 24 hours were significantly different between the controls (31.6±2.3%) and cirrhotics without hepatoma (4.7±1.6%) and cirrhotics with hepatoma (8.6±3.0%) (p<0.001 and p<0.001, respectively).Excretion of each metabolite was also significantly reduced in the cirrhotics without and hepatoma (p<0.001 and p<0.01, respectively). Mean values for % total conjugation of antipyrine was significantly reduced in the cirrhotics without and with hepatoma (p<0.001 and p<0.001, respectively). These results indicate that capacity for conjugation of antipyrine metabolites as well as that for antipyrine oxidation reduce in the patients with cirrhosis than in the control subjects.
財団法人日本消化器病学会の論文